Molecular Partners AG Receivables

Molecular Partners AG (MOLN) currently reports a receivables of $1.3M as of June 2026. That compares with $3.6M in the prior-year period — down 62.9% year over year. Use the charts on this page to explore Molecular Partners AG's receivables history and peer comparisons.

Molecular Partners AG's receivables decreased from $3.6M to $1.3M — a 62.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Molecular Partners AG reported $1.3M in receivables as of June 2026. That compares with $3.6M in the prior-year period — down 62.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Molecular Partners AG, and consider following MOLN for alerts when major investors trade the stock.

Molecular Partners AG is classified in the Healthcare sector. On receivables, it currently shows $1.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MOLN with unrelated industries.